Tag: CLL

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

sarah JonasResearch Results

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.

Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

sarah JonasResearch Results

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.